Goodwin Biotechnology, Inc. is a fully integrated contract manufacturer of monoclonal antibodies and vaccines; Goodwin Biotechnology has the experience and expertise in development of recombinant proteins and antibody drug conjugates.
Goodwin Biotechnology has almost 20 years of experience in the field of biotechnology whereas RAFAGEN, Inc. is a well known leader in cell line engineering for protein monoclonal antibody drug production; RAFAGEN's main aim is the development and commercialization of next generation gene expression systems.
PhD, Soo Young Lee, Senior vice president of Goodwin Biotechnology Inc. expressed that by collaborating with RAFAGEN for cell line engineering they can expand their horizons and capabilities as biological contract manufacturing company.
Both the companies recently announced their collaboration agreement for the cell line engineering and biological contract manufacturing.
© Idaho National Laboratory
Tanzania has the best technology regulator regimes which are likely to be destabilized for commercial interests. Mr Moses Shaha, Regional Chairman Eastern and Southern Africa Small Scale Farmers' Forum (ESAFF), said that the relaxing regulations which govern GMOs are counterproductive as biotechnology companies focus on commercial interests. ESAFF is an umbrella organization of activists opposed to GMOs. The future of biotechnology regulator regime is debated and many experts and activists are giving their opinions about the biotechnology.
This financial year, Govt. has allocated 30 billion for research under Commission for Biotechnology. Tanzania Alliance for Biodiversity members consider that Biosafety regulations for biotechnology should be based on precautionary principle. The Alliance conducts and supports similar movements in South Africa, Zambia, Kenya, and Uganda, to resist the Africa-wide pressure from the US-driven biotechnology industry.
© IRRI Images
Seattle based company Geospiza has been around the block a time or two in the bioinformatics business, and after 14 years in the game, it has come to the end of the road.
The bioinformatics company, which makes software for scientists who analyze data from genetic experiments, said last week it has agreed to be acquired by Waltham-based PerkinElmer, the giant maker of tools for life scientists.
© Kate Cooper
"Genomic information is becoming increasingly important in understanding and treating disease,'' said Richard Begley, PerkinElmer's president of emerging technologies and bioinformatics, in a statement.
Geospiza has been one of the small and persistent voices in the market that has insisted biologists need better software to manage genomic information and PerkinElmer provides just this especially for bioinformatics. The company struggled to get traction with this argument in the wake of the Human Genome Project of bioinformatics, but was able to weather the storm as competitors fell by the wayside, and the market eventually became more attractive